• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

FDA Approves Second Treatment for Ebola Virus

Article

The FDA approved ansuvimab-zykl (Ebanga; Ridgeback Biotherapeutics) for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children.

Officials with the FDA have approved ansuvimab-zykl (Ebanga; Ridgeback Biotherapeutics) for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children, according to a press release.

Ansuvimab-zykl is the second treatment to receive FDA approval for the treatment of Ebola virus. A monoclonal antibody mixture composed of atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb; Regeneron) was approved in October 2020.

Ansuvimab-zykl, a human monoclonal antibody, was evaluated in the PALM clinical trial amid the Ebola outbreak in the Democratic Republic of the Congo in 2018-2019.

In the multi-center, open-label, randomized controlled PALM study, 174 patients (120 adults and 54 pediatric patients) with confirmed Ebola virus infection received ansuvimab-zykl intravenously as a single 50 mg/kg infusion, and 168 participants (135 adults and 33 pediatric patients) received an investigational control. Of those patients who received ansuvimab-zykl, 35.1% died after 28 days, compared with 49.4% of the patients who received a control therapy.

The most commonly reported adverse effects (AEs) in the trial include fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills; however, these are also common symptoms of the Ebola virus infection, according to the FDA.

According to the FDA, patients who receive ansuvimab-zykl should avoid the concurrent administration of a live virus vaccine against Ebola virus, as there is a potential for the drug to inhibit replication of a live vaccine virus and possibly reduce the efficacy of the vaccine.

Reference:

  1. FDA Approves Treatment for Ebola Virus. News release. FDA; December 21, 2020. Accessed December 22, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-treatment-ebola-virus

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Dr. Charles Lee
© 2023 MJH Life Sciences

All rights reserved.